Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study

Purpose: To assess the impact of transjugular intrahepatic portosystemic shunt (TIPS) on clinical outcomes and liver histology in patients with hepatic sinusoidal obstruction syndrome (HSOS) caused by pyrrolizidine alkaloids (PA), and compare these results with those of patients who received support...

Full description

Bibliographic Details
Main Authors: Chaoyang Wang, Yingliang Wang, Jianbo Zhao, Chongtu Yang, Xiaoli Zhu, Huanzhang Niu, Junhui Sun, Bin Xiong
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023106633
_version_ 1797337008054468608
author Chaoyang Wang
Yingliang Wang
Jianbo Zhao
Chongtu Yang
Xiaoli Zhu
Huanzhang Niu
Junhui Sun
Bin Xiong
author_facet Chaoyang Wang
Yingliang Wang
Jianbo Zhao
Chongtu Yang
Xiaoli Zhu
Huanzhang Niu
Junhui Sun
Bin Xiong
author_sort Chaoyang Wang
collection DOAJ
description Purpose: To assess the impact of transjugular intrahepatic portosystemic shunt (TIPS) on clinical outcomes and liver histology in patients with hepatic sinusoidal obstruction syndrome (HSOS) caused by pyrrolizidine alkaloids (PA), and compare these results with those of patients who received supportive treatment alone. Materials and methods: From June 2015 to August 2022, 164 patients diagnosed with PA-HSOS in six tertiary care centers were retrospectively included in this study and divided into TIPS group (n = 69) and supportive treatment (ST) group (n = 95). The main endpoint was to determine whether TIPS placement could improve survival in PA-HSOS patients. The clinical symptoms associated with portal hypertension were also evaluated in this study. Additionally, a small TIPS-subgroup of 7 patients received liver biopsies before and after TIPS for histological analysis. Results: The incidence of death was markedly lower in the TIPS group than in the ST group (log-rank p = 0.026). Multivariate Cox model revealed that group assignment (hazard ratio (HR) 5.146; 95 % confidence interval (CI) 1.587–16.687; p = 0.006), total bilirubin (HR 1.029; 95 % CI 1.020–1.038; p < 0.001), and INR (HR 13.291; 95 % CI 3.637–48.566; p < 0.001) were independent predictors for mortality. In addition, TIPS placement reduced the risk of complications associated with portal hypertension but did not increase the rate of overt hepatic encephalopathy (log-rank p = 0.731). Furthermore, six of 7 TIPS patients receiving liver biopsies improved after TIPS placement, and one patient developed fibrosis. Conclusions: TIPS placement decreased the mortality and risk of complications associated with portal hypertension. Histological evaluation in a few patients showed a potential improvement by TIPS.
first_indexed 2024-03-08T09:03:10Z
format Article
id doaj.art-1e3518e8f6b94bfaa3597520b6844c37
institution Directory Open Access Journal
issn 2405-8440
language English
last_indexed 2024-03-08T09:03:10Z
publishDate 2024-01-01
publisher Elsevier
record_format Article
series Heliyon
spelling doaj.art-1e3518e8f6b94bfaa3597520b6844c372024-02-01T06:31:57ZengElsevierHeliyon2405-84402024-01-01101e23455Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective studyChaoyang Wang0Yingliang Wang1Jianbo Zhao2Chongtu Yang3Xiaoli Zhu4Huanzhang Niu5Junhui Sun6Bin Xiong7Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, ChinaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, ChinaDepartment of Vascular and Interventional Radiology, Nanfang Hospital, Southern Medical University, Guangzhou, 510000, ChinaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, 471000, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhejiang University, Hangzhou, 310000, ChinaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China; Department of Interventional Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China; Corresponding author. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue #1277, Wuhan 430022, China. And Department of Interventional Radiology, The First Affiliated Hospital of Guangzhou Medical University, Jiangxi Avenue #151, Guangzhou, 510000, China.Purpose: To assess the impact of transjugular intrahepatic portosystemic shunt (TIPS) on clinical outcomes and liver histology in patients with hepatic sinusoidal obstruction syndrome (HSOS) caused by pyrrolizidine alkaloids (PA), and compare these results with those of patients who received supportive treatment alone. Materials and methods: From June 2015 to August 2022, 164 patients diagnosed with PA-HSOS in six tertiary care centers were retrospectively included in this study and divided into TIPS group (n = 69) and supportive treatment (ST) group (n = 95). The main endpoint was to determine whether TIPS placement could improve survival in PA-HSOS patients. The clinical symptoms associated with portal hypertension were also evaluated in this study. Additionally, a small TIPS-subgroup of 7 patients received liver biopsies before and after TIPS for histological analysis. Results: The incidence of death was markedly lower in the TIPS group than in the ST group (log-rank p = 0.026). Multivariate Cox model revealed that group assignment (hazard ratio (HR) 5.146; 95 % confidence interval (CI) 1.587–16.687; p = 0.006), total bilirubin (HR 1.029; 95 % CI 1.020–1.038; p < 0.001), and INR (HR 13.291; 95 % CI 3.637–48.566; p < 0.001) were independent predictors for mortality. In addition, TIPS placement reduced the risk of complications associated with portal hypertension but did not increase the rate of overt hepatic encephalopathy (log-rank p = 0.731). Furthermore, six of 7 TIPS patients receiving liver biopsies improved after TIPS placement, and one patient developed fibrosis. Conclusions: TIPS placement decreased the mortality and risk of complications associated with portal hypertension. Histological evaluation in a few patients showed a potential improvement by TIPS.http://www.sciencedirect.com/science/article/pii/S2405844023106633Transjugular intrahepatic portosystemic shuntHepatic sinusoidal obstruction syndromePyrrolizidine alkaloidsMulticenter
spellingShingle Chaoyang Wang
Yingliang Wang
Jianbo Zhao
Chongtu Yang
Xiaoli Zhu
Huanzhang Niu
Junhui Sun
Bin Xiong
Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study
Heliyon
Transjugular intrahepatic portosystemic shunt
Hepatic sinusoidal obstruction syndrome
Pyrrolizidine alkaloids
Multicenter
title Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study
title_full Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study
title_fullStr Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study
title_full_unstemmed Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study
title_short Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study
title_sort transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids a multicenter retrospective study
topic Transjugular intrahepatic portosystemic shunt
Hepatic sinusoidal obstruction syndrome
Pyrrolizidine alkaloids
Multicenter
url http://www.sciencedirect.com/science/article/pii/S2405844023106633
work_keys_str_mv AT chaoyangwang transjugularintrahepaticportosystemicshuntforthetreatmentofhepaticsinusoidalobstructionsyndromecausedbypyrrolizidinealkaloidsamulticenterretrospectivestudy
AT yingliangwang transjugularintrahepaticportosystemicshuntforthetreatmentofhepaticsinusoidalobstructionsyndromecausedbypyrrolizidinealkaloidsamulticenterretrospectivestudy
AT jianbozhao transjugularintrahepaticportosystemicshuntforthetreatmentofhepaticsinusoidalobstructionsyndromecausedbypyrrolizidinealkaloidsamulticenterretrospectivestudy
AT chongtuyang transjugularintrahepaticportosystemicshuntforthetreatmentofhepaticsinusoidalobstructionsyndromecausedbypyrrolizidinealkaloidsamulticenterretrospectivestudy
AT xiaolizhu transjugularintrahepaticportosystemicshuntforthetreatmentofhepaticsinusoidalobstructionsyndromecausedbypyrrolizidinealkaloidsamulticenterretrospectivestudy
AT huanzhangniu transjugularintrahepaticportosystemicshuntforthetreatmentofhepaticsinusoidalobstructionsyndromecausedbypyrrolizidinealkaloidsamulticenterretrospectivestudy
AT junhuisun transjugularintrahepaticportosystemicshuntforthetreatmentofhepaticsinusoidalobstructionsyndromecausedbypyrrolizidinealkaloidsamulticenterretrospectivestudy
AT binxiong transjugularintrahepaticportosystemicshuntforthetreatmentofhepaticsinusoidalobstructionsyndromecausedbypyrrolizidinealkaloidsamulticenterretrospectivestudy